Active Biotech AB
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Quinoline carboxamides for use in the treatment of leukemia (US 10,300,053) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Dec 11, 2026The maintenance fee for Quinoline carboxamides for use in the treatment of multiple myeloma (US 10,314,836) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
- 1 fee due Feb 20, 2027The maintenance fee for Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors (US 10,385,069) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 2 fees due Apr 20, 2027
- 1 fee due Sep 15, 2027The maintenance fee for N-ETHYL-N-PHENYL-1,2-Dihydro-4,5-DI-HYDROXY-1-Methyl-2-OXO-3-Quinolinecarboxamide, Preparation and Uses Thereof (US 9,284,276) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,383,645 | Stable laquinimod preparations In force · From the USPTO record | In force | From the USPTO record | |
| US 7,989,473 | Stable Laquinimod Preparations In force · High confidence | In force | High confidence | |
| US 9,340,307 | Stable Laquinimod Preparations In force · Low confidence | In force | Low confidence | |
| US 8,354,428 | Novel Solid State Forms of Laquinimod and Its Sodium Salt In force · High confidence | In force | High confidence | |
| US 8,178,127 | Stable Laquinimod Preparations In force · High confidence | In force | High confidence | |
| US 8,871,936 | Method for manufacturing of quinoline-3-carboxamides In force · From the USPTO record | In force | From the USPTO record | |
| US 9,585,878 | Treatment of BDNF-related disorders using laquinimod In force · High confidence | In force | High confidence | |
| US 9,284,276 | N-ETHYL-N-PHENYL-1,2-Dihydro-4,5-DI-HYDROXY-1-Methyl-2-OXO-3-Quinolinecarboxamide, Preparation and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,161,935 | Use of Laquinimod for Treating Crohn's Disease Patients Who Failed First-Line Anti-Tnf Therapy In force · High confidence | In force | High confidence | |
| US 9,161,936 | Laquinimod for Treatment of Gaba Mediated Disorders In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 20: 1 patent in force now held by others · 18 lapsed for an unpaid fee · 23 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 3 abandoned · 6 no status recorded